Elicit has raised $9.0M in total across 1 funding round.
Elicit's investors include Afore Capital, Andreessen Horowitz, Banana Capital, Craft Ventures, General Catalyst, Dan Cahana, Glenn Solomon, Plaid, Preston-Werner Ventures.
Elicit is an AI-powered platform designed for scientific research, enabling users to search, summarize, extract data from, and chat with over 125 million academic papers.[1][2] It serves over 2 million researchers in academia and industry, addressing the challenge of efficiently navigating vast scientific literature by automating tasks like systematic literature reviews, paper screening, and data extraction, with users reporting up to 80% time savings.[1][2] The company has raised $22M in Series A funding and $9M additionally to expand beyond academia into industries like pharma, medtech, consumer goods, industrials, and software, while achieving SOC 2 Type II certification for security.[1]
Elicit generates customizable research reports inspired by systematic reviews and supports workflows for literature reviews, paper search, libraries, alerts, and reports, positioning it as a tool for evidence-based reasoning across domains.[1][2]
Elicit emerged as a focused AI tool for scientific research, with consistent product launches—nearly one user-facing feature per week since 2021—demonstrating a commitment to rapid iteration.[1] The company has secured significant funding, including $9M to advance its mission of using language models to accelerate reliable scientific reasoning, followed by a $22M Series A to build AI infrastructure for broader industries.[1] While specific founder details are not detailed in available sources, Elicit's evolution reflects a pivot from academia-centric tools to multi-industry applications, marked by milestones like SOC 2 certification and expansion into practical research automation.[1][2]
Elicit's strengths lie in its specialized AI capabilities tailored for rigorous scientific workflows:
These features enable deep customization, such as altering papers or data in reports, setting it apart in a crowded AI landscape.[2]
Elicit rides the wave of AI-driven knowledge synthesis, particularly in research-heavy fields amid exploding scientific output (over 125 million papers accessible).[1][2] Its timing aligns with surging demand for evidence-based tools in pharma, medtech, and industrials, where manual literature reviews bottleneck innovation—Elicit counters this by speeding reasoning and enabling cross-industry applications like materials discovery or algorithmic improvements.[1][2] Market forces like advancing language models and regulatory needs for transparent AI (e.g., SOC 2) favor it, while its influence grows by empowering researchers at top institutions, potentially standardizing AI in systematic reviews and fostering faster R&D cycles ecosystem-wide.[1][2]
Elicit is poised to deepen industry penetration post-Series A, likely enhancing AI infrastructure for non-academic sectors like pharma and consumer goods with features for real-time data analysis and workflow automation.[1] Trends in multimodal AI (e.g., integrating OCR or advanced reasoning) and regulatory pushes for cited, auditable research will propel it, potentially expanding to enterprise-scale evidence platforms. Its influence may evolve from research accelerator to core infrastructure for scientific decision-making, amplifying human expertise in a data-flooded world—building on its foundation as the go-to AI for credible, scalable literature mastery.[1][2]
Note: Search results distinguish this Elicit (AI research firm) from unrelated entities like Elicit Technology (CargoWise logistics partner founded 2013 in India).[3][4][5] Analysis focuses on the primary AI company matching the query.
Elicit has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $9.0M Seed | Afore Capital, Andreessen Horowitz, Banana Capital, Craft Ventures, General Catalyst, Dan Cahana, Glenn Solomon, Plaid, Preston-Werner Ventures |
